🇺🇸 FDA
Pipeline program

ENTECAVIR , Placebo to VAY736 150 mg/1 mL Solution for injection in pre-filled syringe, TENOFOVIR DISOPROXIL , TENOFOVIR ALAFENAMIDE , -, VAY736

CVAY736S12201

Phase 2 small_molecule active

Quick answer

ENTECAVIR , Placebo to VAY736 150 mg/1 mL Solution for injection in pre-filled syringe, TENOFOVIR DISOPROXIL , TENOFOVIR ALAFENAMIDE , -, VAY736 for Diffuse cutaneous systemic sclerosis (dcSSc) is a Phase 2 program (small_molecule) at Novartis Ophthalmics Europe with 1 ClinicalTrials.gov record(s).

Program details

Company
Novartis Ophthalmics Europe
Indication
Diffuse cutaneous systemic sclerosis (dcSSc)
Phase
Phase 2
Modality
small_molecule
Status
active

Clinical trials